The important role of operations in the management of anaplastic thyroid carcinoma

被引:81
作者
Sugino, K
Ito, K
Mimura, T
Nagahama, M
Fukunari, N
Kubo, A
Iwasaki, H
Ito, K
机构
[1] Ito Hosp, Div Surg, Shibuya Ku, Tokyo 1508308, Japan
[2] Keio Univ, Sch Med, Dept Radiol, Tokyo, Japan
[3] Yokohama City Univ, Med Ctr, Dept Gen Surg, Kanagawa, Japan
关键词
D O I
10.1067/msy.2002.119936
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Anaplastic thyroid carcinoma is a rare and highly lethal neoplasm. We investigated whether operations have an impact on the survival of patients who have anaplastic carcinoma without distant metastasis. Methods. Between 1989 and 1999, 40 consecutive patients with anaplastic carcinoma, without distant metastasis at the time of presentation or during local treatment, were reviewed. The cumulative survival rates and 1-year survival rates were compared. Results. Eleven patients had a small focus of anaplastic carcinoma in a differentiated carcinoma, and 29 patients had ordinary anaplastic thyroid carcinoma. Surgical debulking was performed in 26 patients. Radiotherapy was used for 31 patients and chemotherapy for 19 patients. The 1-year survival rates of the patients with incidental anaplastic carcinoma, ordinary anaplastic carcinoma who underwent operations, and ordinary anaplastic carcinoma who did not undergo operations were 73 %, 60 %, and 21 %, respectively. A significantly higher cumulative survival rate was observed in patients with incidental anaplastic carcinoma than in those with ordinary anaplastic carcinoma. A significantly better outcome was obtained by surgical debulking of ordinary anaplastic carcinoma. Conclusions. Patients with incidental anaplastic carcinoma tended to have a good outcome, but some had a poor prognosis. Surgical debulking improved the outcome of patients with ordinary anaplastic carcinoma.
引用
收藏
页码:245 / 248
页数:4
相关论文
共 23 条
[1]
Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo [J].
Ain, KB ;
Tofiq, S ;
Taylor, KD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3650-3653
[2]
Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].
Ain, KB ;
Egorin, MJ ;
DeSimone, PA .
THYROID, 2000, 10 (07) :587-594
[3]
ALDINGER KA, 1978, CANCER-AM CANCER SOC, V41, P2267, DOI 10.1002/1097-0142(197806)41:6<2267::AID-CNCR2820410627>3.0.CO
[4]
2-7
[5]
ANAPLASTIC THYROID-CARCINOMA - A STUDY OF 70 CASES [J].
CARCANGIU, ML ;
STEEPER, T ;
ZAMPI, G ;
ROSAI, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 83 (02) :135-158
[6]
DEMETER JG, 1991, SURGERY, V110, P956
[7]
KIM JH, 1983, CANCER, V52, P954, DOI 10.1002/1097-0142(19830915)52:6<954::AID-CNCR2820520603>3.0.CO
[8]
2-D
[9]
Kobayashi T, 1996, HEAD NECK-J SCI SPEC, V18, P36, DOI 10.1002/(SICI)1097-0347(199601/02)18:1<36::AID-HED5>3.0.CO
[10]
2-#